These findings demonstrate that semaglutide is effective across the full spectrum of patients with obesity-related HFpEF, from those who do not require loop diuretics to those with significant congestion, requiring high-dose loop diuretic therapy, often with adjunctive MRA and SGLT2 inhibitor use. This evidence concerns the gene SLC5A2 and obesity disorder.